nature structural & molecular biology

Article

Time-resolved cryo-EM (TR-EM) analysis of substrate polyubiquitination by the RING E3 anaphase-promoting complex/cyclosome (APC/C)

Received: 20 December 2022

Accepted: 21 August 2023

Published online: 21 September 2023

Check for updates

Tatyana Bodrug^{1,2}, Kaeli A. Welsh², Derek L. Bolhuis^{1,2}, Ethan Paulakonis², Raquel C. Martinez-Chacin², Bei Liu^{2,8}, Nicholas Pinkin², Thomas Bonacci², Liying Cui², Pengning Xu², Olivia Roscow³, Sascha Josef Amann⁴, Irina Grishkovskaya^{® 4}, Michael J. Emanuele^{® 2}, Joseph S. Harrison^{® 5}, Joshua P. Steimel⁶, Klaus M. Hahn^{® 2}, Wei Zhang³, Ellen D. Zhong^{® 7}, David Haselbach^{® 4} & Nicholas G. Brown^{® 2}

Substrate polyubiquitination drives a myriad of cellular processes, including the cell cycle, apoptosis and immune responses. Polyubiquitination is highly dynamic, and obtaining mechanistic insight has thus far required artificially trapped structures to stabilize specific steps along the enzymatic process. So far, how any ubiquitin ligase builds a proteasomal degradation signal, which is canonically regarded as four or more ubiquitins, remains unclear. Here we present time-resolved cryogenic electron microscopy studies of the 1.2 MDa E3 ubiquitin ligase, known as the anaphase-promoting complex/cyclosome (APC/C), and its E2 co-enzymes (UBE2C/UBCH10 and UBE2S) during substrate polyubiquitination. Using cryoDRGN (Deep Reconstructing Generative Networks), a neural network-based approach, we reconstruct the conformational changes undergone by the human APC/C during polyubiquitination, directly visualize an active E3-E2 pair modifying its substrate, and identify unexpected interactions between multiple ubiquitins with parts of the APC/C machinery, including its coactivator CDH1. Together, we demonstrate how modification of substrates with nascent ubiquitin chains helps to potentiate processive substrate polyubiquitination, allowing us to model how a ubiquitin ligase builds a proteasomal degradation signal.

The processivity of molecular machines is paramount to the countless biological processes that enable life. Molecular machines, such as polymerases, ribosomes or proteasomes, commonly use nucleotide-directed motors to potentiate key steps in processive reactions, for example, translocation of substrates^{1,2}. Recent advances in cryogenic electron microscopy (cryo-EM) have enabled the description of the physical properties of these machines^{3,4}. Thus far, conformations seem to be Boltzmann distributed, without large thermodynamic barriers, and molecules can sample the full space, implying microscopic reversibility at every conformational step⁵. Directionality comes from kinetic asymmetries in processes that stabilize specific conformational states, for example, nucleotide hydrolysis⁶.

A full list of affiliations appears at the end of the paper. e-mail: david.haselbach@imp.ac.at; nbrown1@med.unc.edu

The fundamentally important ubiquitin (Ub) ligases do not directly bind or hydrolyze nucleotides as a part of their mechanism but still maintain forward-driven, processive activity⁷⁻¹². The complete conformational landscape for any of the >600 Ub ligases during polyubiquitination is unknown¹³. Our current understanding of how these enzymes maintain processivity and ensure that ubiquitination proceeds in a directional manner is therefore incomplete.

Substrate ubiquitination requires Ub to be passed along a cascade of E1, E2 and E3 enzymes¹⁴. E3 enzymes serve as a hub for substrate recognition and directly mediate the transfer of Ub from the E2 to the substrate¹⁵. A key Ub ligase known as the anaphase-promoting complex/cyclosome (APC/C) drives the cell cycle by recognizing important substrates, for example, cyclin B and securin, and ubiquitinating them to mark them for proteasomal degradation^{16,17}. Degradation of such substrates controls cell cycle timing, including mitosis and G1 maintenance^{18,19}. A key determining factor in the timing of APC/C substrate degradation is the efficiency of Ub signal formation on the substrate and whether it occurs in a processive or distributive manner^{8,9,11,20}. This Ub signal can vary through modification of numerous lysines on the substrate or through different Ub linkages (for example, K11, K48, K63 or K11/K48 branched chains)²¹⁻²³. During a processive ubiquitination cycle, the substrate binds to APC/C coactivators (CDC20 in mitosis and CDH1 in interphase) and APC10 (refs. 8,24,25). The binding of the coactivator elicits a conformational change in the cullin-RING (CRL) subunits APC2-APC11, which promotes the binding of the first E2, UBE2C/UBCH10, that adds Ub directly to the substrate (Fig. 1a)²⁶⁻²⁸. UBE2C can either continue to modify substrate lysines or make short chains^{21,29-31}. A second E2, UBE2S, extends the K11-linked Ub chains on the substrate³²⁻³⁴. These reactions can all occur during a single substrate-binding event while the E2s require multiple rounds of transient binding and catalysis to modify the substrate.

A proteasome degradation signal is typically regarded as a substrate that is modified with four or more Ubs³⁵. A structure of an E3 building such signal remains elusive. So far, the structures of APC/C with either UBE2C or UBE2S, and other E3–E2 pairs, have mostly relied on chemical crosslinking approaches to lock the dynamic enzymes in place^{23,27,36–40}. These studies allow for high-resolution structural determination of active catalytic architectures but limit our understanding of the conformational landscape and driving forces of E3-mediated polyubiquitination. A single molecule study of APC/C-dependent polyubiquitination revealed that substrate-linked Ub(s) enhance the processivity of the ubiquitination reaction by improving the substrate binding affinity or processive affinity amplification⁷. However, the precise coordination of Ub-binding sites, of E2 binding and of Ub transfer by the APC/C or any E3 to build a proteasome degradation signal remains largely undescribed.

In this Article, we performed time-resolved cryo-EM (TR-EM) experiments to watch the APC/C in action and understand its structural and biophysical properties during substrate polyubiquitination. By combining TR-EM with in vitro ubiquitination assays and total internal reflection fluorescence (TIRF) microscopy, our work provides the framework for a sculpted energy landscape, where particularly low-energy (highly populated) intermediates are not observed along the reaction path of APC/C-dependent polyubiquitination. In general, macromolecular machines such as the APC/C coordinate dynamic equilibrium within flexible domains with stochastic binding of E2s to carry out their activity. These types of molecular systems therefore exhibit highly multimodal heterogeneity. We show that the APC/C couples the thermal noise power of its flexible domains with transient stabilizing interactions and with the emerging Ub-modified substrate to drive processivity. Allosteric changes upon binding of coactivators and the chain elongating E2 UBE2S potentiate this processivity. Together, these interactions allow us to create a model for how APC/C builds a proteasomal degradation signal.

Results

Structure of the APC/C actively ubiquitinating a substrate

The APC/C and its E2s can perform a vast number of different ubiquitination reactions^{21-23,29-34,41}. Trapping each of these individual structural states has required detailed biochemical knowledge about the system to stabilize the reaction intermediates^{23,27,36-38,42}. Given the multiple substrate and Ub lysine target sites, the number of potential ubiquitination states that would require artificial trapping is huge. Furthermore, generating structures of later stages of substrate ubiquitination to help define the determinants of processivity would require complex protein engineering to form different Ub chain linkage types. We therefore sought to solve structures of the APC/C and its E2s performing polyubiquitination over a time course to examine its conformational heterogeneity, identify unknown states of polyubiquitination and uncover interactions between the substrate-linked Ub and the APC/C machinery.

To generate TR-EM samples of the APC/C during substrate ubiquitination, we preincubated two mixtures, one containing the APC/C, CDH1 and substrate, and a second containing the E1, UBE2C, Mg-ATP and Ub (Fig. 1b). For a substrate, the fluorescently labeled CycB N-terminus (Ub-CycB^{N*}) containing a fused Ub was used to ensure that additional observed interactions resulted from the formation of polyubiquitination rather than the initial substrate priming step (Extended Data Fig. 1a). To examine the impact of UBE2S on the structural landscape of APC/C^{CDH1}, a second reaction was performed that included UBE2C and UBE2S. The two mixtures were combined to start the reaction, and samples were taken from the reaction at specific timepoints (0.5, 1.5, 5 and 15 min), applied to a grid and plunge frozen. Visualization of the reaction on sodium dodecyl sulfatepolyacrylamide gel electrophoresis (SDS-PAGE) showed an expected difference between the two time courses, with the presence of both E2s resulting in longer Ub chains than UBE2C alone (Fig. 1c). Both reactions showed differences in levels of Ub modification between the initial and later stages of the reaction. Single-particle electron microscopy (EM) data were then collected from each grid at each timepoint (Extended Data Fig. 1b).

The data collected on a Titan Krios resulted in 25,380 and 25,900 movies for the reaction mixtures containing APC/C^{CDH1}-Ub-CycB^N-UBE2C and APC/C^{CDH1}-Ub-CycB^N-UBE2C-UBE2S, respectively (Extended Data Fig. 1b,c). After multiple rounds of classification to filter each dataset down to ~600.000-700.000 particles, we were able to solve high-resolution consensus structures (3-4 Å) for each dataset (Extended Data Fig. 1d-f and Table 1). Because of prior work, we were able to build the structure of APC/C interacting with its coactivator CDH1 and UBE2C for both datasets (Fig. 1d and Extended Data Fig. 1f). The coactivator N- and C-terminal tails are also resolved in their respective binding sites, with the CDH1 IR tail localized on APC3 and the CDH1 C-box bound to APC8 (Fig. 1d, i and ii) (ref. 27). The D-box of CycB is seen bound to the CDH1-APC10 groove and UBE2C is clasped by the APC11 RING and APC2 WHB (Fig. 1d, iii) (refs. 23,27,38). However, a key difference between these two structures (Fig. 1d and Extended Data Fig. 1f) and previous work is that UBE2C is not artificially trapped through chemical crosslinking or through genetic fusion to either APC11 or the UBE2S C-terminus^{23,27,38}. Density for the UBE2S C-terminal peptide (CTP) is visible in the groove formed by APC2-APC4 in the dataset containing both E2s (Fig. 1d, iv) (refs. 23,27). Therefore, our structures validate prior work that relied on chemical crosslinking with UBE2C and UBE2S and reveal structures of an E3-E2-E2 complex actively ubiquitinating a substrate, indicating that both E2s can bind the APC/C simultaneously^{23,27,38}.

When comparing the structure of APC/C-CDH1-UBE2C from this study to those of the same complex from two previous studies (EMD-2925 and EMD-2929), the structures were similar, with map-to-map



Fig. 1 | **TR-EM reveals structure of APC/C-CDH1-UBE2C-UBE2S^{CTP} during substrate polyubiquitination. a**, Cartoon representation of reaction cycle carried out by the APC/C as it ubiquitinates substrates. The transition from the 'CRL (cullin–RING) down' inactive conformation to the 'CRL up' active conformation is facilitated by coactivator binding. Initiation of ubiquitination on target substrates is carried out by the recruitment of UBE2C-Ub by the APC2 WHB (winged-helix B) and APC11 RING domains. UBE2S elongates chains initiated by UBE2C. **b**, Overview of TR-EM approach. Two mixtures containing the reaction components are incubated at room temperature (1). The mixtures are combined to start the reaction (2). Samples are taken from the reaction at timepoints indicated and applied to a grid (3) that is then plunge frozen (4) and imaged using cryo-EM. Representative samples were taken at the time the grids were plunge frozen for SDS-PAGE (5), shown in **c. c**, Fluorescent monitoring of an SDS-PAGE gel showing APC/C^{CDHI}-E2 (UBE2C or both UBE2C and UBE2S)-dependent substrate modification at each timepoint for which a grid was frozen. At least three experimental replicates were repeated to optimize conditions. Uncropped gel image available in source data. **d**, 3D reconstruction of particles from the filtered APC/C-CDH1-UBE2C-UBE2S dataset at 3.5 Å showing the active catalytic architecture assembled. Atomic models of key subunits and ubiquitination components fitted into the cryo-EM density, including CDH1 bound to the APC/C scaffold (i and ii), UBE2C clamped by the APC2 WHB and APC11 RING domains (iii), and the UBE2S CTP bound to the groove formed by APC2 (green) and APC4 (light pink) (iv).

correlations of either 0.76 or 0.81 (Extended Data Fig. 1g)^{23,27,38}. When we compared the structures of APC/C-CDH1-UBE2C and APC/C-CDH1-UBE2C-UBE2S generated from the two datasets in this study, we observed a map-to-map correlation of 0.93 (Extended Data Fig. 1h). In other words, the reaction that contained UBE2S did not reveal extra density for the UBE2S catalytic core. The observed density for the UBE2S^{CTP} in our APC/C-CDH1-UBE2C-UBE2S structure

did agree with structures from previous studies where it was resolved (Extended Data Fig. 1i). Ultimately, this is consistent with the previous kinetic work suggesting that the UBE2S^{CTP} provides the affinity for UBE2S to bind to the APC/C, suggesting that the intrinsic kinetic differences (on and off rates) between E2 and E3 interactions are a potential limiting factor to solving structures of E3–E2 pairs actively ubiquitinating a substrate^{23,27,42,43}. These differences could be due to either

Table 1 | Cryo-EM data collection, refinement and validation statistics

	#1 APC/C-CDH1- UBE2C	#2 APC/C-CDH1- UBE2C-UBE2S
	(EMD-41140), (PDB 8TAR)	(EMD-41142), (PDB 8TAU)
Data collection and processing		
Magnification	180,000×	180,000×
Voltage (kV)	300	300
Electron exposure (e ⁻ Å ⁻²)	42	42
Defocus range (µm)	-0.7 to -3.5	-0.7 to -3.5
Pixel size (Å)	0.82	0.82
Symmetry imposed	C1	C1
Initial particle images (no.)	2,001,820	1,894,448
Final particle images (no.)	661,289	774,933
Map resolution (Å)	4.0 Å	3.5 Å
FSC threshold	0.143	0.143
Map resolution range (Å)	3–10 Å	3–10 Å
Refinement		
Initial model used (PDB code)	7QE7	7QE7
Model resolution (Å)	4.0 Å	3.5 Å
FSC threshold	0.143	0.143
Model resolution range (Å)	3–10 Å	3–10 Å
Map sharpening B factor (Å ²)	-188.3	-159.6
Model composition		
Non-hydrogen atoms	35,965	36,038
Protein residues	8,989	9,007
R. m. s. deviations		
Bond lengths (Å)	0.006	0.007
Bond angles (°)	0.766	0.792
Validation		
MolProbity score	1.70	1.81
Clashscore	6.84	9.17
Ramachandran plot		
Favored (%)	98.19%	97.89%
Allowed (%)	1.81%	2.12%
Disallowed (%)	0.00%	0.00%

binding interactions or the type of ubiquitination occurring, that is, ubiquitinating the target directly versus building a polyubiquitin chain.

Total heterogeneity reveals a sculpted energy landscape

To provide further insight into the conformational landscape of the APC/C and its E2s and understand processive polyubiquitination, we examined the structural heterogeneity of the APC/C during catalysis in the two datasets using cryoDRGN (Deep Reconstructing Generative Networks)³. The cryoDRGN method learns a mapping of particle images into a low-dimensional continuous vector space, termed the latent space, and an associated neural network volume representation that can reconstruct a 3D density volume from any point in this latent space, allowing for the visualization of a unique 3D map for each particle (Extended Data Fig. 2a). The full dataset's latent space representation can be visualized in 2D using dimensionality reduction techniques such as principal component analysis (PCA) and uniform manifold

approximation and projection (UMAP)⁴⁴. The distribution of structures can be further analyzed by *k*-means clustering on the latent space representation, with particles classified into various states based on their cluster assignments. For each of the two time courses, particles across all timepoints were combined and used to train the neural network. UMAP visualization of the latent space for both time courses revealed a continuous, featureless surface, suggesting a convoluted landscape with high degrees of overlap between the distribution of structures across time points (Extended Data Fig. 2b,c). A comprehensive sampling of 500 structures from the latent space at the *k*-means cluster centers (k = 500) showed largely similar compositional and conformational variability between the datasets and recapitulated several known APC/C conformations (Extended Data Fig. 2b,c).

Trajectories generated along the principal components of the latent space captured the broad conformational changes of the APC/C. For example, the trajectory along the first component (PC1) shows the continuous motion through which the APC2 CRL domain (the C-terminus of APC2) transitions from the 'CRL down' to the 'CRL up' conformation (Fig. 2a). Along the second component (PC2), the APC2 CRL can be visualized transitioning from an intermediate, partially raised 'CRL up' conformation to the fully raised 'CRL up' conformation with clear density for UBE2C present (Extended Data Fig. 2d and Supplementary Video 1).

By applying PCA on the 500 volumes generated at the k-means cluster centers, we were able to uncover interesting aspects of conformational variability of the APC/C (Extended Data Fig. 3). Along the first volume PC trajectory, we can trace the binding of the coactivator together with the simultaneous displacement of the APC2 CRL domain from the 'down' to the 'up' conformation, resulting in a ~15 Å displacement. The second volume PC trajectory follows a CDH1-bound state where the CRL is partially in the 'up' conformation and undergoes an ~11 Å displacement to the 'CRL up' conformation. The third and fourth PCs map heterogeneity at the coactivator and the catalytic core, with CDH1 displacements of ~10 and ~11 Å visualized, respectively. Changes in density present near the coactivator and contacts made and broken between the components involved in the catalytic core (CDH1, UBE2C, APC11, APC2^{CRL} and APC10) are also visualized, demonstrating the power of cryoDRGN for visualizing complex heterogeneity. Extra density, particularly near the coactivator and UBE2C visualized in PC3 and PC4, suggests heterogeneity at the catalytic core due to the presence of substrate and Ub.

A systematic analysis of the 500 cryoDRGN volumes revealed four major conformational states: APC/C with the APC2^{CRL} domain in a 'CRL down' conformation, an APC/C^{CDHI}. 'CRL up' conformation, and two categories of states where either APC7, located at the top of the APC, or the APC2 CRL-APC11 RING domains showed high degrees of variability (labeled 'Partial APC7 and 'CRL unresolved', respectively) (Fig. 2b and Extended Data Fig. 4). While the biological relevance of the 'Partial APC7' and 'CRL unresolved' states is currently unclear, some differences within these states can be noted. For example, the classes where APC2-APC11 are unresolved all contained CDH1. Additionally, extra density was observed around the coactivator and the APC2 N-terminal domain remained clearly resolved, suggesting the potential for dynamics within the APC2-APC11 domains that are not captured by our methods.

The mapping of the four major states onto the UMAP visualization of the particle distribution in the latent space revealed a convoluted landscape with some degree of overlap between the states (Fig. 2c,d). Interestingly, the mapping of the distribution of the states relative to one another was preserved in the landscapes of both datasets. Between the two datasets, the one containing only UBE2C showed higher fractions of particles in the 'Partial APC7' and 'CRL unresolved' states, suggesting a potential role for UBE2S in stabilizing these domains or the APC/C overall (Fig. 2e,f). Both datasets showed similar levels of 'CRL down' particles. Overall, the distribution of particles within the states changed relatively little across the timepoints, suggesting an energy landscape void of new highly populated APC/C intermediates ($\Delta\Delta G < 2 k_B T$) in the mixture in any of the possible conformational states at a given time and regardless of the extent of overall substrate ubiquitination. This observation suggests that polyubiquitination is not a process with large energy barriers, and instead the reactions are stochastic, with thermal noise and allostery due to the simultaneous binding of multiple components driving the conformational states. Thus, directionality in the processivity of the reaction needs to be introduced by different means than energy barriers.

UBE2C association with APC/C is increased by CDH1 and UBE2S

Further analysis of the volumes from k-means clustering major states revealed additional characteristics about APC/C conformational dynamics. The 'CRL down' major state clusters could be subdivided into two substates: an apo state that showed no density near APC10 that could be attributed to CDH1 and a small minority of clusters that did show density consistent with CDH1 bound (Fig. 3a and Extended Data Fig. 5a). The much higher level of 'CRL down' in the apo 'CDH1 unbound' state is consistent with previous data showing that coactivator binding mediates the transition from the 'CRL down' to the 'CRL up' states^{26,28}. For the 'CRL up' state, where we expect that allostery through binding is a directing force, we examined if the composition of these states is altered by the presence of UBE2S, as suggested previously⁴⁵. When UBE2S is present, the UBE2C-bound fraction is slightly increased at each timepoint (Fig. 3b and Extended Data Fig. 5b). In the reaction without UBE2S, UBE2C is present in ~40% of the particles. When UBE2S is added, UBE2C is present in ~50-60% of the particles over the time course. This finding suggests that UBE2S improves the association of UBE2C with the APC/C and potentiates multiubiguitination.

To investigate cooperative interactions between the APC/C^{CDH1}associated E2s on a single-molecule level, we developed a TIRF microscopy-based system. Briefly, a fluorescently labeled, biotinylated substrate (biotin-CycB^N*) was immobilized within flow chambers functionalized with neutravidin (Fig. 3c). UBE2C labeled with JaneliaFluor549 (UBE2C-IF549) was mixed with ubiguitination reaction components, including unlabeled APC/C, then added to the flow cells immediately before data acquisition. These tagged and labeled reagents retained their functionality in substrate ubiquitination reactions (Extended Data Fig. 5c). Within the flow chamber, APC/C^{CDH1} will bind the immobilized substrate and recruit UBE2C-IF549 from solution to the slide surface for ubiquitination. Therefore, fluorescence signal events at the slide surface provide a readout of UBE2C-IF549 recruitment by APC/C^{CDH1}. We observed minimal background fluorescence from the functionalization process, robust signal from immobilized biotin-CycB^{N*}, and minimal signal from the fluorescent substrate in the UBE2C channel, indicating that our TIRF system allows for a clear delineation between substrate and E2 signals at the slide surface (Extended Data Fig. 5d-h).

Next, we sought to assess how the UBE2S^{CTP} impacts UBE2C recruitment by titrating a UBE2S^{CTP} 18mer peptide into the reaction. Addition of the UBE2S^{CTP} substantially increased the total events of UBE2C localizing to the slide surface, indicating that the UBE2S^{CTP} enhances

Fig. 2 | **Reconstruction of a functional conformational landscape of APC/C-CDH1-mediated polyubiquitination using cryoDRGN. a**, PCA representation of the particle distribution in latent space with explained variance (EV) noted in parentheses. The first component captures the continuous conformational changes the APC/C undergoes in the 'CRL down' to 'CRL up' transition. Density for APC2, APC11 and CDH1 are shown at indicated points as green, blue and purple, respectively. b, 3D models generated using homogeneous 3D refinement of each set of major state particles. Density maps are colored by proximity to the subunit indicated as modeled using rigid body fitting. **c,d**, Left: UMAP representation of the particle distribution in latent space UBE2C recruitment to APC/C^{CDHI}-bound substrate (Fig. 3d, Extended Data Fig. 5f and Supplementary Video 2). This result supports prior work that UBE2S is capable of stimulating UBE2C activity through its unique binding arrangement on the APC/C⁴⁵. Altogether, we demonstrate coordination between UBE2C and the UBE2S^{CTP} at APC/C^{CDHI} and present a flexible system to study substrate-dependent interactions with single-molecule resolution. Furthermore, this system corroborates our structural data that UBE2S assists in stabilizing the 'CRL up' conformation, permitting UBE2C to bind the APC/C.

APC/C^{CDH1}–UBE2C structures mediating polyubiquitination

So far, most structures of RING E3s bound to an E2 involve an unmodified substrate mimicking substrate priming or a monoubiquitinated substrate to mimic monoubiquitination, multiubiquitination (targeting multiple lysines on a substrate), or specific chain elongation (Extended Data Fig. 6a)^{23,27,36-40}. Since our datasets involve the entire polyubiquitination process, we rationalized that localized classification approaches would help us identify APC/C structures further along polyubiquitination than ever before. This processing resulted in unexpected insights into RING E3–E2-dependent polyubiquitination.

Local classification using a mask around the active site resulted in a set of unprecedented structures for APC/C–UBE2C-mediated polyubiquitination. In addition to known interactions, multiple additional Ub interactions were identified. First, a Ub is bound to the RING domain on the opposite side of the UBE2C-binding site (Fig. 4a, left). This finding is particularly interesting as prior work relied on a tight-binding ubiquitin variant (UbV) to observe this interaction²³. Next, we observed unexpected density consistent with the size and shape of Ub at the coactivator, suggesting a potential Ub-binding site (Fig. 4a, center left). Additional density is observed between the coactivator and the C-terminal region of UBE2C known as the Helix-Turn-Helix (HTH) (Fig. 4a, center right). Intriguingly, a subset of particles contained density where seemingly a di-Ub contacts both the coactivator and the E2 simultaneously (Fig. 4a, right).

As Ub binding can modulate the activity of E2s and E3s, these potential Ub interactions with either APC11 RING, UBE2C or CDH1 could have unappreciated effects on APC/C-dependent ubiquitination. Since we previously identified that Ub can interact with the APC11 RING domain and the HTH from other E2s (refs. 23,46), we sought to examine the function of the unexpected Ub-binding site on CDH1. As tight-binding UbVs have been tremendously helpful in disentangling the regulation of the several enzymes of the Ub system^{23,47-50}, including the APC11 RING domain, we selected a library of UbVs against both APC/C coactivators, CDH1 and CDC20 (Fig. 4b). This process revealed a UbV (henceforth known as UbV^{CDH1}) that was substantially enriched during the selection (Fig. 4c). To validate that UbV^{CDH1} interacts with the coactivators in a manner similar to wild-type Ub, we performed a series of tests. First, a co-pulldown assay found that a GST-UbV $^{\mbox{\scriptsize CDH1}}$ fusion bound both CDC20 and CDH1 better than the GST-Ub fusion (Fig. 4d). Because the binding site of UbV^{CDH1} is potentially in proximity to the KEN-box degron binding site, we expected UbV^{CDH1} to inhibit APC/C-mediated ubiquitination. Consistent with this hypothesis, UbV^{CDH1} inhibited APC/C substrate degradation in mitotic extracts of HeLaS3 cells (Fig. 4e). Conversely, substrate degradation rates were not

clustered using *k*-means (*k* = 500) clustering and then classified into the four major APC/C states present within the APC/C^{CDHI}–UBE2C (**c**) and APC/C^{CDHI}– UBE2C–UBE2S (**d**) datasets. Points denote cluster centers where volumes were generated. Right: subplots of particle distributions separated by major states. Particle distributions for each class are colored by their local density overlayed onto the particle distribution for the entire dataset (gray). **e**,**f**, Top: charts show distribution of particles across major states for the APC/C^{CDHI}–UBE2C (**e**) and APC/C^{CDHI}–UBE2C–UBE2S (**f**) datasets. Bottom: line graphs show change in relative fraction of each major state over time in the two datasets.





Fig. 3 | **UBE2S CTP enhances the APC/C 'CRL up' state, increasing the association of UBE2C-Ub with APC/C-CDH1. a,b**, Quantification of substates within the APC/C 'CRL up' and 'CRL down' major states assigned from 500 sampled cryoDRGN volumes. 'CRL down' clusters partition into a majority of particles where CDH1 is absent (-80%). The 'CRL up' particles contain a minor subset of particles where the CRL is only partially in the 'up' position (**a**). Addition of UBE2S increases the relative number of particles with density attributed to UBE2C present in the clusters compared to the absence of UBE2S (**b**). **c**, Schematic of TIRF microscopy substrate immobilization and the localization of ubiquitination reaction components. Alexa488-labeled CycB^N is immobilized to a neutravidin-functionalized slide through an N-terminal, biotinylated Avitag (captured using a 488 nm laser; substrate channel). APC/C-CDH1 will localize to

the substrate and subsequently recruit fluorescent UBE2C–JF549 (captured using a 561 nm laser; UBE2C channel) and a UBE2S^{CTP} peptide that binds the APC2/APC4 groove. Thus, the number of binding events in the UBE2C channel correlates to UBE2C localizing to APC/C–CDH1–substrate. **d**, Titrating the UBE2S^{CTP} increases the recruitment of UBE2C to APC/C–CDH1, localized to substrate at the slide surface. Quantification of the total number of UBE2C binding events (Extended Data Fig. 5f) from three independent experiments is shown (see Supplementary Video 2 for representative movies and Extended Data Fig. 5g,h for single molecule binding event montage and representative traces). Error bars: standard error of the mean. Data are normalized to the control where APC/C-CDH1 is absent. Experiments were compared using one-way analysis of variance (**P* = 0.0176).

influenced by the presence or absence of excess Ub upon the addition of UBE2C (Extended Data Fig. 6b).

UbV^{CDH1} was then used as surrogate to determine the structure of APC/C^{CDH1} bound to Ub. To optimize UbV^{CDH1} for structural studies, we tested if UbV^{CDH1} could be fused to either the KEN-box or D-box of Hsl1, an APC/C substrate, to further strengthen its interaction with the APC/C. As expected, the UbV^{CDH1}–Hsl1 D-box fusion markedly inhibited APC/C-mediated substrate ubiquitination compared to either the UbV^{CDH1} alone or the UbV^{CDH1}-Hsl1 KEN-box fusion (Fig. 4f and Extended Data Fig. 6c). Therefore, APC/C^{CDH1} bound to UbV^{CDH1}– Hsl1 D-box was subjected to cryo-EM. As expected, the Hsl1 D-box was bound between APC10 and CDH1 and the UbV^{CDH1} was bound to CDH1 near the KEN-box binding site (Fig. 4g and Extended Data Fig. 6d). These data are consistent with the ubiquitination assays showing that the UbV^{CDH1}–Hsl1 KEN-box fusion weakly inhibited the APC/C-mediated substrate ubiquitination compared to UbV^{CDH1} alone (Fig. 4f and Extended Data Fig. 6c).

Multiple Ub-binding sites promote processive ubiquitination

With the identification of multiple Ub-binding sites, we wanted to explore their contributions to APC/C-dependent ubiquitination. In addition to UbV^{CDH1}, another UbV (henceforth known as UbV^{RING}) was previously developed to bind to the APC11 RING exosite and was used to trap structures of the APC/C with UBE2C and UBE2S (ref. 23). To specifically examine how these Ub-binding sites synergize to

promote ubiquitination, we used these two UbVs to specifically disrupt these Ub-dependent interactions (Fig. 5a). First, we performed single-encounter experiments to specifically interrogate the different effects of the two UbVs in either substrate priming (the addition of the first Ub) or processive polyubiquitination. APC/C, CDH1 and a fluorescently labeled substrate are preincubated separately from a mixture of E1, E2, MgATP, Ub and a large excess of nonfluorescent substrate (Fig. 5b). Therefore, only the substrate that is preincubated with APC/C is modified during a single binding event. As expected, the UbV^{RING} reduced the number of Ubs added to the substrate during processive ubiquitination but did not disrupt substrate priming (Fig. 5c,d and Extended Data Fig. 7a). Surprisingly, the UbV^{CDH1} inhibited both reactions even though the fluorescent substrate is preincubated with APC/C^{CDH1}. We then performed substrate-independent experiments to determine if the observed inhibition is specific to substrate ubiquitination or another step in the Ub cascade. Both the APC/C-dependent hydrolysis of an oxyester version of UBE2C-Ub and di-Ub synthesis by APC/C-UBE2S were unimpeded by the UbV^{CDH1} (Extended Data Fig. 7b,c). Therefore, we tested the ubiquitination of several substrates in multiple turnover experiments and found that all substrates were inhibited by UbV^{CDH1} (Extended Data Fig. 7d). To specifically test the degron dependence of these effects, we purified degron variants of Ub-Securin. Interestingly, the addition of both UbVs inhibits Ub-Securin ubiquitination when both degrons were mutated, indicating that the UbVs are preventing substrate recruitment through the added Ub





Cyclin B, Geminin and Securin in mitotic HeLa cell extracts was inhibited by the addition of UbV^{CDHI}, but not Ub, as monitored by immunoblotting. n = 3independent experiments. **f**, Attachment of the Hsl1 D-box, but not the Hsl1 KEN-box, to UbV^{CDHI} potentiates its inhibition of APC/C–CDH1–UBE2C-mediated substrate ubiquitination, monitored in three independent experiments by fluorescent scanning of an SDS–PAGE gel. **g**, Left: the cryo-EM structure of APC/C-CDH1 bound to the UbV^{CDHI} (orange)–Hsl1 D-box (red) shows the localization of UbV^{CDHI} near the KEN-box-binding site on the CDH1 β -propeller (purple). Right: previously published cryo-EM map of APC/C bound to CDH1 and Hsl1 (EMD-2651) for comparison²⁸. Uncropped gels representative of n = 3independent experiments for **d–f** available in source data.



Fig. 5 | Multiple Ub-binding sites promote processive ubiquitination by APC/C^{CDH1}. a, Cartoon model showing binding sites of CDH1-binding (UbV^{CDH1}) and APC11-binding (UbV^{RING}) UbVs. **b**. Workflow for single-encounter experiments. APC/C^{CDH1} and *CycB^N containing multiple lysines or a single lysine (1K) are preincubated. The UbVs were added to this mixture. A second mix is prepared containing E1, UBE2C, MgATP, an excess of unlabeled Hsl1, and Ub or methylated Ub (meUb). The mixtures are combined, resulting in fluorescent substrate ubiquitination during a single binding event. c, Fluorescent scanning of an SDS-PAGE gel (top) and quantification (bottom) from single-encounter APC/C-CDH1-UBE2C-dependent polyubiquitination reactions with CycB^{N*} and Ub. Dashed box indicates the region of $CycB^{N*}$ with >4 Ubs quantified in Extended Data Fig. 7a. n = 3 independent experiments. Error bars: standard error of the mean. d, Fluorescent scanning of an SDS-PAGE gel (top) and quantification (bottom) from single encounter of APC/C-CDH1-UBE2C-dependent substrate priming reactions with CycB^{N*}(1K) and meUb. n = 3 independent experiments. Error bars: standard error of the mean. e, APC/C-CDH1-dependent ubiquitination reactions of Ub-Securin with its KEN- and D-box degrons mutated (Ub-Securin KD^{mut*}) using either UBE2C (left) or UBE2S (right), monitored

by fluorescent scanning. n = 3 independent experiments. f, Ubiquitination of fluorescently labeled *UbV^{CDH1} by APC/C-UBE2C is dependent on CDH1 and the APC2 WHB, monitored by fluorescent scanning, n = 3 independent experiments. g, METRIS setup to monitor binding of APC/C to a biotinylated substrate, Ub-substrate or Ub on a streptavidin-coated surface. Magnetic beads with biotinylated APC/C are subjected to a magnetic field. The movement of individual beads is quantitated to determine a rolling parameter (RP) that correlates with the strength of the interaction. h, i, Scatter plots quantitating the RP of the APC/C on surfaces containing $CycB^{N}$ or Ub-Cyc B^{N} (**h**) or Ub (**i**) in the presence of UbV^{RING}, UbV^{CDH1} or both. Experiments were compared using one-way analysis of variance (**** $P \le 0.0001$, *** $P \le 0.001$, ** $P \le 0.005$, * $P \le 0.05$). NS, not significant. j, Schematic of APC/C-CDH1-UBE2C-UBE2S-dependent substrate polyubiquitination. The APC/C catalytic architecture and recruitment of UBE2C-Ub (dUb) is influenced by CDH1 and UBE2S CTP binding to drive ubiquitination efficiency. Allosterically driven processivity of ubiquitination is further mediated by stabilizing contacts between multiple substrate-linked Ubs and CDH1 and APC11. Uncropped gels representative of n > 3 independent experiments for **c**-**f** available in source data.

(Fig. 5e and Extended Data Fig. 7e). However, UbV^{CDH1} inhibited Ub–Securin KEN^{Mut}/D^{Mut} ubiquitination more than the UbV^{RING} when UBE2C was used as the E2, suggesting that the UbV^{CDH1} has additional inhibitory mechanisms.

Our experiments suggested that UbV^{CDH1} could also serve as an acceptor, receiving Ub from UBE2C instead of UBE2S. To support our hypothesis, a fluorescently labeled version of UbV^{CDH1} (*UbV^{CDH1}) was subjected to ubiquitination by APC/C–UBE2C. Indeed, *UbV^{CDH1} could be modified in both a CDH1- and APC2 WHB-dependent manner (Fig. 5f). These results reveal that the CDH1 and RING Ub-binding sites promote substrate binding and improve the processivity of the APC/C. Additionally, the coactivator-bound Ub can also serve as an acceptor for Ub chain formation by UBE2C, but not UBE2S (Extended Data Fig. 7f).

Given that these interactions with Ub are probably very weak on their own, we turned to an innovative technique called mechanically transduced immunosorbent assay (METRIS) to examine the role of Ub-binding sites in providing additional affinity for the substrate⁵¹. METRIS is a single-particle method that can provide relative, but quantitative, assessments of binding with high statistical power. Biotinylated APC/C^{CDH1} was used to coat magnetic beads, then added to a functionalized surface of either CycB^N or Ub-CycB^N, and subjected to a rotating magnetic field. The distance the bead rolls is indicative of the strength of the protein-protein interaction and is noted as the rolling parameter (RP) (Fig. 5g). Ub-CycB^N displayed a significant increase in its RP (0.21 \pm 0.007) compared to CycB^N (0.15 \pm 0.004), supporting the idea that Ub enhances substrate binding (Fig. 5h). Additionally, when the UbVs were added to competitively remove this noted increase, only UbV^{CDH1} substantially reduced the RP to 0.19 ± 0.007 , which is still higher than the RP of APC/C^{CDH1} to CycB^N (Fig. 5h). To focus on the role of CDH1 in promoting the binding between APC/C and Ub, we performed experiments in the presence or absence of CDH1 and only used Ub on the functionalized surface. As expected, the addition of CDH1 to the APC/C enhanced the RP between the APC/C and Ub from 0.14 ± 0.004 to 0.17 ± 0.006 (Fig. 5i). Furthermore, the addition of both UbVs completely eliminated this improvement in the RPs to background levels (0.13 ± 0.003) , suggesting that both the APC11 RING and CDH1 contribute to Ub binding. Combined, these findings suggest that multimodal interactions between substrate-linked Ubs and the coactivators, as well as the APC/C itself, work together to stabilize the emerging Ub chain and facilitate the processivity and efficiency with which the APC/C modifies its substrates (Fig. 5j).

Discussion

To interpret molecular mechanisms, data from structural biology approaches, for example, X-ray crystallography or cryo-EM, are combined with information from biochemical or biophysical assays. Structural studies deliver static snapshots of chemically or thermodynamically stabilized machines. Biochemical assays can only monitor a restricted set of atomic arrangements within the machine at the same time. E3 Ub ligases are under intense regulation through transiently binding cofactors and perform many tasks, including recruiting different substrates, interacting with multiple E2s and forming different types of Ub chains. Therefore, trying to connect biochemical assays with structural studies to understand processive reactions remains challenging. Furthermore, understanding the driving forces and resolving key intermediate states of an evolving, Ub-modified substrate remains largely elusive. To combat this problem, we performed TR-EM experiments of the APC/C actively polyubiquitinating a substrate with its E2s.

Instead of chemically trapping the APC/C in a distinct polyubiquitination architecture, we examined APC/C^{CDH1} modifying Ub-CycB^N over a time course through manual plunge freezing. Using advanced deep-learning approaches for analyzing structural heterogeneity, we were able to generate a functional conformational landscape, revealing a sculpted energy landscape without high-energy populated intermediates, suggesting the absence of new thermodynamic barriers for APC/C-mediated polyubiquitination with either UBE2C or both E2s. These landscapes are stochastic with few minima or barriers. Instead, we hypothesize that thermal noise is the primary driving force and changes in the substrate, Ub and E2 interactions result in subtle allosteric changes to the APC/C scaffold that are difficult to distinctly classify. In short, there is one mode of action of the APC/C that can mediate several tasks, and subtle changes in the immediate environment, such as the ubiquitination state of the substrate or E2 bindings, modulate its function. This type of landscape can also be readily tunable by additional regulators. Since the APC/C is tightly regulated by multiple kinases, phosphatases and inhibitors, each component may only slightly alter the conformational landscape or result in different conformational pathways during different stages of the cell cycle^{18,52}. While there are methodological limitations inherent to any structural method, for example, the air-water interface in cryo-EM, we reproduced several known states on the basis of structures that have been prepared in different ways from different groups, providing support for our workflow. Future work performing this type of analysis on analogous E3s can reveal how different binding partners and post-translational modifications, such as cullin neddylation, stabilize their active states^{40,53}.

It was previously shown by single-molecule studies of APC/C-dependent ubiquitination that substrate-linked Ubs either help drive further catalysis through processive affinity amplification or track the Ub chain^{7,54}. Our analysis revealed one previously discovered Ub-binding site on APC11 and two potential Ub-binding sites on the coactivator and UBE2C HTH²³. We speculate that these potential Ub-binding sites could be used to enhance the processivity of polyubiquitination by increasing the substrate binding affinity for the APC/C, as suggested by our METRIS data. However, these Ub-binding sites could have additional roles during polyubiquitination. For example, Ub binding to the UBE2C^{HTH} might also allosterically modulate UBE2C activity. The Ub-coactivator interaction could similarly have multiple implications. First, because UbV^{CDH1} can serve as an acceptor, the coactivator could be presenting the Ub in a particular orientation for short chain elongation by UBE2C. Alternatively, the Ub-binding sites might be positioned in a manner to allow the substrate lysine to be modified by UBE2C instead of the Ub. This hypothesis is potentially interesting as the Ub-binding site on the coactivator is near the substrate KEN-box binding site. Since the APC/C coactivators are a key point of regulation by the cell and facilitate substrate recruitment to the APC/C, these additional Ub-binding interactions are probably subject to a series of small changes in the reaction environment and may facilitate the variety of polyubiquitination outcomes of APC/C-dependent reactions, for example, cell cycle progression. Taken together, Ub-binding sites on the substrate receptor may be a recurring theme across E3 ligases as it may help control the extent of polyubiquitination.

Several known interactions were not present in our current processing, suggesting there are probably many additional insights present in this dataset. For example, Ub binding to the APC2 WHB was not observed in our refinements⁴⁷. Additionally, while we observed UBE2C bound to the APC/C in both datasets, the UBE2S core was never observed even though the UBE2S^{CTP} was clearly visible. The UBE2S core binds very weakly to APC2, but the UBE2S^{CTP} binds tightly to the APC2–APC4 groove^{23,27,42}. Nonetheless, both E2s were bound in the APC/C^{CDH1}–UBE2C–UBE2S polyubiquitination dataset. As substrate priming is typically regarded as the slow step, while chain elongation is relatively quicker, our work suggests that intrinsic differences in the reaction and/or binding kinetics of the E2s is a limiting factor for this type of approach for different E2–E3 pairs^{10,12,55}.

In conclusion, we examined APC/C-mediated substrate polyubiquitination through an innovative approach, revealing the conformational landscape for substrate polyubiquitination by the APC/C. The APC/C is regulated throughout the cell cycle, and a sculpted landscape is perhaps necessary to finely tune its activity in different contexts. Furthermore, the processivity of polyubiquitination does not come directly through nucleotide binding and/or hydrolysis but rather the Ub binding to the E3. It is well established that E3 ligases are modulated by post-translational modifications and protein–protein interactions. Therefore, as we revealed several fundamental insights into APC/C-mediated polyubiquitination in relatively few experiments, we expect this method will be useful for the future studies of other E3s.

Online content

Any methods, additional references, Nature Portfolio reporting summaries, source data, extended data, supplementary information, acknowledgements, peer review information; details of author contributions and competing interests; and statements of data and code availability are available at https://doi.org/10.1038/s41594-023-01105-5.

References

- Alberts, B. & Miake-Lye, R. Unscrambling the puzzle of biological machines: the importance of the details. *Cell* 68, 415–420 (1992).
- Frank, J. The translation elongation cycle-capturing multiple states by cryo-electron microscopy. *Philos. Trans. R. Soc. Lond. B* 372, 20160180 (2017).
- Zhong, E. D., Bepler, T., Berger, B. & Davis, J. H. CryoDRGN: reconstruction of heterogeneous cryo-EM structures using neural networks. *Nat. Methods* 18, 176–185 (2021).
- Kaledhonkar, S. et al. Late steps in bacterial translation initiation visualized using time-resolved cryo-EM. *Nature* 570, 400–404 (2019).
- Fischer, N., Konevega, A. L., Wintermeyer, W., Rodnina, M. V. & Stark, H. Ribosome dynamics and tRNA movement by time-resolved electron cryomicroscopy. *Nature* 466, 329–333 (2010).
- 6. Astumian, R. D. Kinetic asymmetry allows macromolecular catalysts to drive an information ratchet. *Nat. Commun.* **10**, 3837 (2019).
- Lu, Y., Wang, W. & Kirschner, M. W. Specificity of the anaphase-promoting complex: a single-molecule study. Science 348, 1248737 (2015).
- Buschhorn, B. A. et al. Substrate binding on the APC/C occurs between the coactivator Cdh1 and the processivity factor Doc1. *Nat. Struct. Mol. Biol.* 18, 6–13 (2011).
- Meyer, H. J. & Rape, M. Processive ubiquitin chain formation by the anaphase-promoting complex. Semin. Cell Dev. Biol. 22, 544–550 (2011).
- Kleiger, G., Saha, A., Lewis, S., Kuhlman, B. & Deshaies, R. J. Rapid E2–E3 assembly and disassembly enable processive ubiquitylation of cullin–RING ubiquitin ligase substrates. *Cell* 139, 957–968 (2009).
- Rape, M., Reddy, S. K. & Kirschner, M. W. The processivity of multiubiquitination by the APC determines the order of substrate degradation. Cell **124**, 89–103 (2006).
- Pierce, N. W., Kleiger, G., Shan, S. O. & Deshaies, R. J. Detection of sequential polyubiquitylation on a millisecond timescale. *Nature* 462, 615–619 (2009).
- 13. Deshaies, R. J. & Joazeiro, C. A. RING domain E3 ubiquitin ligases. Annu. Rev. Biochem. **78**, 399–434 (2009).
- Haakonsen, D. L. & Rape, M. Branching out: improved signaling by heterotypic ubiquitin chains. *Trends Cell Biol.* 29, 704–716 (2019).
- Baek, K., Scott, D. C. & Schulman, B. A. NEDD8 and ubiquitin ligation by cullin–RING E3 ligases. *Curr. Opin. Struct. Biol.* 67, 101–109 (2020).
- Peters, J. M. SCF and APC: the Yin and Yang of cell cycle regulated proteolysis. *Curr. Opin. Cell Biol.* **10**, 759–768 (1998).
- King, R. W., Deshaies, R. J., Peters, J. M. & Kirschner, M. W. How proteolysis drives the cell cycle. Science 274, 1652–1659 (1996).

- Bodrug, T., Welsh, K. A., Hinkle, M., Emanuele, M. J. & Brown, N. G. Intricate regulatory mechanisms of the anaphase-promoting complex/cyclosome and its role in chromatin regulation. *Front. Cell Dev. Biol.* 9, 687515 (2021).
- Primorac, I. & Musacchio, A. Panta rhei: the APC/C at steady state. J. Cell Biol. 201, 177–189 (2013).
- Williamson, A. et al. Regulation of ubiquitin chain initiation to control the timing of substrate degradation. *Mol. Cell* 42, 744–757 (2011).
- Kirkpatrick, D. S. et al. Quantitative analysis of in vitro ubiquitinated cyclin B1 reveals complex chain topology. *Nat. Cell Biol.* 8, 700–710 (2006).
- 22. Meyer, H. J. & Rape, M. Enhanced protein degradation by branched ubiquitin chains. *Cell* **157**, 910–921 (2014).
- Brown, N. G. et al. Dual RING E3 architectures regulate multiubiquitination and ubiquitin chain elongation by APC/C. *Cell* 165, 1440–1453 (2016).
- 24. da Fonseca, P. C. et al. Structures of APC/C(Cdh1) with substrates identify Cdh1 and Apc10 as the D-box co-receptor. *Nature* **470**, 274–278 (2011).
- 25. Visintin, R., Prinz, S. & Amon, A. CDC20 and CDH1: a family of substrate-specific activators of APC-dependent proteolysis. *Science* **278**, 460–463 (1997).
- 26. Li, Q. et al. WD40 domain of Apc1 is critical for the coactivator-induced allosteric transition that stimulates APC/C catalytic activity. *Proc. Natl Acad. Sci. USA* **113**, 10547–10552 (2016).
- Chang, L., Zhang, Z., Yang, J., McLaughlin, S. H. & Barford, D. Atomic structure of the APC/C and its mechanism of protein ubiquitination. *Nature* 522, 450–454 (2015).
- Chang, L. F., Zhang, Z., Yang, J., McLaughlin, S. H. & Barford, D. Molecular architecture and mechanism of the anaphase-promoting complex. *Nature* 513, 388–393 (2014).
- 29. Aristarkhov, A. et al. E2-C, a cyclin-selective ubiquitin carrier protein required for the destruction of mitotic cyclins. *Proc. Natl Acad. Sci. USA* **93**, 4294–4299 (1996).
- Yu, H., King, R. W., Peters, J. M. & Kirschner, M. W. Identification of a novel ubiquitin-conjugating enzyme involved in mitotic cyclin degradation. *Curr. Biol.* 6, 455–466 (1996).
- Dimova, N. V. et al. APC/C-mediated multiple monoubiquitylation provides an alternative degradation signal for cyclin B1. *Nat. Cell Biol.* 14, 168–176 (2012).
- Wu, T. et al. UBE2S drives elongation of K11-linked ubiquitin chains by the anaphase-promoting complex. *Proc. Natl Acad. Sci. USA* 107, 1355–1360 (2010).
- Garnett, M. J. et al. UBE2S elongates ubiquitin chains on APC/C substrates to promote mitotic exit. *Nat. Cell Biol.* 11, 1363–1369 (2009).
- 34. Williamson, A. et al. Identification of a physiological E2 module for the human anaphase-promoting complex. *Proc. Natl Acad. Sci. USA* **106**, 18213–18218 (2009).
- 35. Martinez-Fonts, K. et al. The proteasome 19S cap and its ubiquitin receptors provide a versatile recognition platform for substrates. *Nat. Commun.* **11**, 477 (2020).
- Yamaguchi, M. et al. Cryo-EM of mitotic checkpoint complex-bound APC/C reveals reciprocal and conformational regulation of ubiquitin ligation. *Mol. Cell* 63, 593–607 (2016).
- 37. Alfieri, C. et al. Molecular basis of APC/C regulation by the spindle assembly checkpoint. *Nature* **536**, 431–436 (2016).
- Brown, N. G. et al. RING E3 mechanism for ubiquitin ligation to a disordered substrate visualized for human anaphase-promoting complex. *Proc. Natl Acad. Sci. USA* **112**, 5272–5279 (2015).
- Streich, F. C. Jr. & Lima, C. D. Structural and functional insights to ubiquitin-like protein conjugation. *Annu. Rev. Biophys.* 43, 357–379 (2014).

Article

- 40. Baek, K. et al. NEDD8 nucleates a multivalent cullin–RING–UBE2D ubiquitin ligation assembly. *Nature* **578**, 461–466 (2020).
- Yau, R. G. et al. Assembly and function of heterotypic ubiquitin chains in cell-cycle and protein quality control. *Cell* **171**, 918–933 e920 (2017).
- 42. Brown, N. G. et al. Mechanism of polyubiquitination by human anaphase-promoting complex: RING repurposing for ubiquitin chain assembly. *Mol. Cell* **56**, 246–260 (2014).
- Frye, J. J. et al. Electron microscopy structure of human APC/C(CDH1)–EMI1 reveals multimodal mechanism of E3 ligase shutdown. Nat. Struct. Mol. Biol. 20, 827–835 (2013).
- McInnes, L., Healy, J. & Melville, J. UMAP: uniform manifold approximation and projection for dimension reduction. Preprint at https://arxiv.org/abs/1802.03426 (2018).
- Martinez-Chacin, R. C. et al. Ubiquitin chain-elongating enzyme UBE2S activates the RING E3 ligase APC/C for substrate priming. *Nat. Struct. Mol. Biol.* 27, 550–560 (2020).
- Welsh, K. A. et al. Functional conservation and divergence of the helix-turn-helix motif of E2 ubiquitin-conjugating enzymes. *EMBO J.* 41, e108823 (2022).
- Watson, E. R. et al. Protein engineering of a ubiquitin-variant inhibitor of APC/C identifies a cryptic K48 ubiquitin chain binding site. Proc. Natl Acad. Sci. USA 116, 17280–17289 (2019).
- 48. Zhang, W. & Sidhu, S. S. Generating intracellular modulators of E3 ligases and deubiquitinases from phage-displayed ubiquitin variant libraries. *Methods Mol. Biol.* **1844**, 101–119 (2018).
- Zhang, W. et al. System-wide modulation of HECT E3 ligases with selective ubiquitin variant probes. *Mol. Cell* 62, 121–136 (2016).
- 50. Ernst, A. et al. A strategy for modulation of enzymes in the ubiquitin system. *Science* **339**, 590–595 (2013).
- 51. Petell, C. J. et al. Mechanically transduced immunosorbent assay to measure protein–protein interactions. *eLife* **10**, e67525 (2021).

- Kataria, M. & Yamano, H. Interplay between phosphatases and the anaphase-promoting complex/cyclosome in mitosis. *Cells* 8, 814 (2019).
- Duda, D. M. et al. Structural insights into NEDD8 activation of cullin–RING ligases: conformational control of conjugation. *Cell* 134, 995–1006 (2008).
- Kelly, A., Wickliffe, K. E., Song, L., Fedrigo, I. & Rape, M. Ubiquitin chain elongation requires E3-dependent tracking of the emerging conjugate. *Mol. Cell* 56, 232–245 (2014).
- 55. Scott, D. C. et al. Two distinct types of E3 ligases work in unison to regulate substrate ubiquitylation. *Cell* **166**, 1198–1214 e1124 (2016).

Publisher's note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons. org/licenses/by/4.0/.

© The Author(s) 2023, corrected publication 2023

¹Department of Biochemistry and Biophysics and Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, NC, USA. ²Department of Pharmacology and Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, NC, USA. ³Department of Pharmacology and Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, NC, USA. ³Department of Molecular and Cellular Biology, College of Biological Science, University of Guelph, Guelph, Ontario, Canada. ⁴Research Institute of Molecular Pathology, Vienna BioCenter, Vienna, Austria. ⁵Department of Chemistry, University of the Pacific, Stockton, CA, USA. ⁶School of Engineering, California Polytechnic State University Humboldt, Arcata, CA, USA. ⁷Department of Computer Science, Princeton University, Princeton, NJ, USA. ⁸Present address: College of Future Technology, National Biomedical Imaging Center, Peking University, Beijing, China. [©]e-mail: david.haselbach@imp.ac.at; nbrown1@med.unc.edu

Methods

Protein purification

Recombinant APC/C was expressed in High Five insect cells (Thermo Scientific) as previously described⁵⁶. APC/C with a Twin-Strep(II)-tag on the APC4 C-terminus was purified via affinity chromatography, ion-exchange chromatography and size exclusion chromatography (SEC). CDH1, UBE2C, UBE2S, UBA1, Ub, methylated Ub, Ub-CycB, Ub-Securin, Securin and CycB were purified as described⁴². For enzyme assays, CDH1 and CDC20 were expressed in baculovirus-infected insect cells with an N-terminal Myc(3x)-Hexahistidine tag and Flag(3x)tag, respectively. CDH1 and CDC20 were then subjected to Ni-NTA or anti-Flag M2 resin, respectively, and the N-terminal tags were removed by HRV 3C protease. The proteins were further purified by ion-exchange chromatography and SEC. For phage display, both CDH1 and CDC20 were purified using an uncleavable Myc(3x)-Hexahistidine tag. GST-UbV^{CDH1} and GST-Ub for co-pulldown experiments were purified using GST-affinity chromatography and SEC. Fluorescent UbV^{CDH1} was conjugated to a fluorescent LPETGG peptide via a sortase-dependent reaction and purified by buffer exchange, Ni-NTA resin and gel filtration to remove sortase and unconjugated $peptide. UbV^{{\rm CDH1}}-Hsl1-degron\,fusions\,were\,designed\,to\,contain\,either$ the Hsl1 D-box (HHHHHHENLYFQSGGGMQIFVKTRKGTSITLEVEPS-DTIENVK

AKIQDKEGIPPDQQRLRFAGKQLEDGRTLSDYNIHNASSLYLRSPL-RALAGGSGSGSSSYLEEQKPKRAALSDITNSFNKMN) or the Hsl1KEN-box (HHHHHENLYFQSGGGRLRISGVSTNKENEGPEYPTKIGSGSGSGSM-QIFVKTRKGTSITLEVEPSDTIENVKAKIQDKEGIPPDQQRLRFAG-KQLEDGRTLSDYNIHNASSLYLRSPLRALAG). Both UbV^{CDH1}–Hsl1D-box and UbV^{CDH1}–Hsl1KEN-box were purified using nickel-affinity chromatography and SEC.

GST-TEV-AviTag-Cyclin B (1-88)-Cys-6xHis or GST-TEV-AviTag-Ub-Cyclin B (1-88)-Cys--6xHis constructs were generated as the substrate to immobilize for TIRF microscopy or METRIS. Once purified, the substrate was biotinylated and fluorescently labeled at the C-terminal cysteine using Alexa488-maleimide.

A UBE2C-LPETGG-6xHis construct was expressed in BL21 (DE3) RIL *Escherichia coli* and purified. UBE2C was conjugated to a polyethylene glycol (PEG) modified peptide (GGGG-PEG-k(N₃)NH₂) through a sortase-dependent reaction and repurified. The UBE2C-LPETGG-PEGk(N₃)NH₂ was fluorescently labeled with JF549 through click chemistry by reacting 50 μ M of UBE2C with 250 μ M CuSO₄, 1.25 mM THPTA and 2.5-fold excess functionalized JF549 dye for 1.5 h on ice. The reaction was quenched with 5 mM ethylenediaminetetraacetic acid and purified using SEC.

Synthesis of reactive Janelia dye JF549

JF549 CO2H (Tocris, 5 mg, 0.0088 mmol) was reacted with Alkyne-PEG-2NH₂ (2.52 mg, 0.0176 mmol) in the presence of diisopropylcarbodiimide (1.633 µl, 0.0106 mmol), N-hydroxysuccinimide (1.52 mg, 0.0132 mmol) and diisopropylethylamine (4.59 µl, 0.026 mmol) in 500 µl of dimethylformamide (Supplementary Fig. 1). The reaction was allowed to stir at room temperature overnight. JF549-Alkyne was purified by high-performance liquid chromatography using a linear gradient of 0-100% A:B (A: 95% H₂O:5% CH₃CN + 0.1% trifluoroacetic acid; B: 95% CH₃CN:5% H₂O + 0.1% trifluoroacetic acid). The solvent was removed by rotary evaporation and further dried under high vacuum. Yield: 4.02 mg, 0.0069 mmol, 78.8%. Nuclear magnetic resonance (NMR) spectra were recorded on a 400 MHz spectrometer. NMR (400 MHz, CDCl₃): δ 2.40 (t, ⁴J = 2.0 Hz, 1H, alkynyl CH), 2.54 (qt, ³J = 7.6 Hz, 4H, azetidinyl b-CH₂), 3.60-3.66 (m, 8H, $-OCH_2CH_2OCH_2CH_2NH$), 4.12 (d, 4J = 2.4 Hz, 2H, propargylic CH₂), 4.22 $(t, {}^{3}J = 7.6 \text{ Hz}, 8\text{H}, \text{ azetidinyl a-CH}_{2}), 6.28 (d, {}^{4}J = 2.0 \text{ Hz}, 2\text{H}), 6.34 (dd, dd)$ ${}^{3}J_{1} = 9.2 \text{ Hz}, {}^{4}J_{2} = 2.0 \text{ Hz}, 2\text{H}, 6.95 (d, {}^{3}J = 9.2 \text{ Hz}, 2\text{H}), 7.64 (brt, {}^{3}J = 4.8 \text{ Hz},$ 1H, CONH-), 7.72 (s, 1H), 8.00 (d, ${}^{3}J$ = 8.4 Hz, 1H), 8.24 (d, ${}^{3}J$ = 8.4 Hz, 1H). Exact mass 580.24421 m/z. Observed mass 580.24484 m/z.

Cryo-EM sample preparation

Time-resolved EM reaction components were combined in two mixes at the following concentrations: 0.7 μ M APC/C, 0.7 μ M CDH1, 1.25 μ M Ub-CycB^{N*} (mix 1) and 2.5 μ M UBE2C, \pm 2.5 μ M UBE2S, 0.2 μ M E1, 16 μ M Ub and 5 mM Mg-ATP (mix 2). Mixes 1 and 2 were incubated for 5 min at room temperature, then combined to start the reaction. Samples were taken at 0.5 s, 1.5 min, 5 min and 15 min, applied to a quantifoil (1.2/1.3) 400 Cu mesh grid, blotted using a Leica plunge freezer and plunge frozen in liquid ethane. Samples were taken for SDS-PAGE at the time of plunge freezing and visualized using a Typhoon fluorescent scanner.

APC/C–CDH1–UbV^{CDH1}–Hsl1D-box complex was prepared by incubating 0.7 μ M APC/C with 1.5 μ M CDH1, 90 μ M UbV^{CDH1}–Hsl1 D-box and 0.005% fluorinated octyl maltoside. The mixture was applied to a quantifoil (1.2/1.3) 200 Cu mesh grid, blotted using a Leica plunge freezer for 2 s and plunge frozen in liquid ethane.

Cryo-EM data acquisition

The grids were imaged using a Titan Krios (Max-Planck Institute for Multidisciplinary Science) on a K2 detector. Images were collected at a nominal magnification of 180,000× and a pixel size of 0.82 Å per pixel. Images contained 39 frames with a total dose of $42 e^- Å^{-2}$. A total of 25,380 micrographs were collected for the APC/C-CDH1-UBE2C dataset and 25,900 micrographs for the APC/C-CDH1-UBE2C-UBE2S dataset (Extended Data Fig. 1b).

EM samples containing APC/C–CDH1–UbV^{CDH1}–Hsl1 D-box were imaged using a Titan Krios G4 (Vienna) with a cold field emission gun and a post-column Selectris energy filter (ThermoFisher) with a 10 V slit, width and a Falcon 4i direct electron detector (ThermoFisher). Images were collected at a magnification of 180,000× and a pixel size of 0.951 Å per pixel, with a cumulative total dose of 40 e⁻ Å⁻².

Image processing

Images for both datasets were motion-corrected using MotionCorr2 in Relion^{57,58}. Contrast transfer function (CTF) correction was done in CryoSPARC using CTFFIND4 (refs. 59–61). 2D classification was carried out in CryoSPARC in three iterative rounds to filter out contamination and bad particles. The particles in the best classes were used to generate an ab initio model, with 661,289 particles in the APC/C–CDH1–UBE2C and 774,933 particles in the APC/C–CDH1–UBE2C–UBE2S dataset. This initial model was then used as a reference for 3D refinement in CryoSPARC, generating a 4.0 Å model for the APC/C–CDH1–UBE2C dataset and 3.5 Å model for the APC/C^{CDH1}–UBE2C–UBE2S dataset (Fig. 1d and Extended Data Fig. 1f). A local resolution map for both final models was generated using the local resolution estimation tool in CryoSPARC (Extended Data Fig. 1d).

Images for the APC/C-CDH1-UbV^{CDH1}-Hsl1 D-box dataset were preprocessed (patch motion correction and CTF estimation) using CryoSPARC Live. 2D classification was carried out in CryoSPARC in 30 iterative rounds to filter out contamination and bad particles. 3D classification was then used to select for particles containing both CDH1 and UbV^{CDH1}-Hsl1 D-box density. Particles in the best class were 3D refined in CryoSPARC, generating a model at 3.88 Å (Fig. 4g).

Model building

Cryo-EM density maps generated using 3D homogeneous refinement were sharpened using deepEMhancer and fit with existing models of APC/C using flexible fitting tools⁶². Initial atomic coordinates for both the APC/C-CDH1-UBE2C and APC/C-CDH1-UBE2C-UBE2S-Ub-CycB^N models were generated using the cryo-EM structure of APC/C-CDH1 (Protein Data Bank (PDB) 7qe7). Models were fitted using the fit-in-map rigid-body fitting tool in UCSF ChimeraX and refined using Isolde^{63,64}. Atomic coordinates for UbV^{CDH1}-Hsl1 D-box were generated using ColabFold structure prediction⁶⁵. The cryo-EM density map for APC/C-CDH1-UbV^{CDH1}-Hsl1 D-box was fitted using rigid body fitting using PDB 5a31 to fit the backbone of the APC/C and CDH1 and the ColabFold-generated structure of UbV^{CDH1}–Hsl1D-box.

CryoDRGN heterogeneity analysis

For cryoDRGN analysis, particles from each dataset were downsampled in CryoSPARC to a 200-pixel box size (2.35 Å per pixel) and used together with CTF parameters and poses from the 3D refinement to train a cryoDRGN eight-dimensional latent variable model for 60 epochs. The encoder and decoder architectures consisted of three hidden layers with 1,024 nodes. The model was analyzed using the cryo-DRGN analysis tools described in Zhong et al.³, to visualize the latent space and generate representative volumes and trajectories. k-Means clustering with k = 500 was used to analyze the latent embeddings of the particles, with volumes generated at the cluster centers using the decoder network to sample the heterogeneity. The latent embedding of the particle distribution was visualized using data dimensionality reduction techniques such as PCA and UMAP (Extended Data Fig. 2b). The cryoDRGN 'analyze landscape' tool was used to carry out PCA on the volumes generated using k-means (k = 500) clustering (Extended Data Fig. 3a). The 500 volumes generated by the k-means clustering analysis were assigned manually to one of four major states ('CRL down', 'CRL up', 'CRL unresolved' and 'Partial APC7). Particles from each of these four major states were extracted and 3D refinements were generated using homogeneous refinement in CryoSPARC, resulting in maps at resolutions of 4.8 Å, 4.1 Å, 4.2 Å and 4.3 Å, respectively (Fig. 2b and Extended Data Fig. 4a). The minor states 'CRL down, CDH1 bound', 'CRL down, CDH1 unbound', 'CRL up, partial', 'CRL up, no UBE2C' and 'CRL up, UBE2C bound' were assigned by visual inspection of the major states.

Coverslip preparation

Glass coverslips (Corning) were cleaned, functionalized through silanization and PEGylation, and assembled into flow chambers for TIRF microscopy experiments. All buffers were 0.22 μ m sterile filtered. Coverslips were sonicated for 30 min in 1 M KOH, 30 min in 200-proof EtOH, then 20 min in deionized (DI) water. Coverslips were silanized by sonicating for 5 min in MeOH, rocked for 12 min in a solution of 93.5% MeOH, 5% acetic acid and 1.5% (3-aminopropyl) triethoxysilane, sonicated for 1 min, rocked in solution for another 12 min, then sonicated for 60 min in DI water. Pairs of coverslips were sandwiched together with a solution of 100 mM NaHCO₃, 500 mM K₂SO₄, 18% succinimidyl valerate–PEG and 0.4% biotin–PEG, then incubated in the dark overnight in humid conditions.

Glass slides (Fisher Scientific) were modified with diamond drill bits to have three pairs of holes on opposite sides of the slide. Thin strips of double-sided tape were laid across the width of the slide on the outside of the holes and between each pair. Functionalized coverslips were washed with DI water, dried and placed on top of the taped slide, then sealed with coverslip sealant to create flow chambers.

Once assembled, flow chambers were incubated with 100 mg ml⁻¹ bovine serum albumin (BSA) in assay buffer (20 mM HEPES pH 8 and 200 mM NaCl, 0.22 μ m filtered) for 30 min, then a 0.5 mg ml⁻¹ neutravidin and 100 mg ml⁻¹ BSA mixture for 5 min, then a 50 nM Cyclin B-Alexa488 and 20 mg ml⁻¹BSA mixture for 2 min. The chambers were washed after each incubation step.

TIRF microscopy

TIRF microscopy was performed on an IX81 Olympus microscope equipped with a 100× TIRF objective (UPLAPO100XOHR, numerical aperture 1.5, Olympus), four solid-state OBIS lasers (Coherent OBIS: 405 nm, 488 nm, 561 nm and 647 nm; controlled via CoherentConnection software), and two scientific complementary metal–oxide– semiconductor cameras for dual-color imaging. The microscope was controlled using MicroManager software⁶⁶.

An initial image of the immobilized substrate within flow chambers was taken with the 488 nm laser at 4 mW power to verify substrate

attachment and determine the region of interest for subsequent analysis. Experiment movies were collected using the 561 nm laser at 2 mW power with 200 ms exposure over a 10 min period after adding reaction components to the flow chamber.

Experimental reactions were made by premixing a phosphomimetic version of APC/C^{36,67} and CDH1 (mix 1), and premixing BSA, UBE2C–JF549 and Ub (mix 2). Final reaction mixtures contained 30 nM pE APC, 100 nM CDH1, 20 mg ml⁻¹BSA, 200 nM UBE2C–JF549, 5 μ M Ub, 100 nM UBA1, 0.8% D-glucose, 5.6 mg ml⁻¹glucose oxidase, 0.34 mg ml⁻¹ catalase, 2 mM TROLOX and a titration of UBE2S CTP. These mixtures were combined with 5 mM ATP-MgCl₂ and added to flow chambers before data acquisition. To validate that our system, ubiquitination of 50 nM biotin–CycB^N–A488 was monitored over a short time course using SDS–PAGE (Extended Data Fig. 5c).

TIRF microscopy data analysis

For each condition, a set of N = 3 experiments were carried out. ImageJ/ FIJI was used to extract a standardized region of interest from experimental movies. In MATLAB 2023a, images were background-subtracted, and single molecules were isolated using an algorithm based on á trous wavelet decomposition⁶⁸. Long-lasting events were linked across frames using a well-established algorithm⁶⁹. Our analysis utilized the MATLAB Curve Fitting Toolbox, Image Processing Toolbox, Microscopy Image Browser, and the Statistics and Machine Learning Toolbox. For each condition, outliers were removed using the ROUT method in GraphPad Prism (Q = 1%) (ref. 70). Detected binding events for each experiment were normalized relative to the condition without APC/C.

Local heterogeneity analysis

Particles assigned the 'CRL up' major state were extracted and imported into CryoSPARC for further analysis⁶¹. Particles were classified into separate 3D classes using the '3D Classification Beta' tool for local classification using a mask including only the catalytic core of the APC/C (CDH1, APC10, UBE2C, APC11 and the APC2^{CRL} domains). Particles from each class were further refined using 3D homogeneous refinement and fitted using rigid body fitting in UCSF ChimeraX.

Ubiquitination assays

In general, fluorescent substrate ubiquitination assays were performed at room temperature, guenched by SDS-containing sample buffer, separated by SDS-PAGE, and visualized using a Typhoon Fluorescence scanner. Ubiquitination assays testing inhibition of substrate polyubiquitination were carried out by mixing 70 nM APC/C, 0.5 µM CDH1, 5 mM ATP/MgCl₂, 1 μM E1, 1 μM UBE2C, 0.5 μM Ub-CycB^{N*}, ±30 μM UbV^{CDH1}, ±Hsl1 D-box, ±Hsl1 KEN-box, ±UbV^{CDH1}–Hsl1 D-box or ±UbV^{CDH1}–Hsl1 KEN-box. A total of 125 μ M Ub was added to start the reaction and quenched after 15 min. Single-encounter assay conditions were carried out by first incubating two separate mixes for 5 min: mix 1 containing APC/C-CDH1, either CycB^{N*} or a version of CycB^{N*} containing a single lysine and $\pm 30 \,\mu\text{M UbV}^{\text{RING}}$ or UbV^{CDH1}, and mix 2 containing 0.1 $\mu\text{M E1}$, 5 µM UBE2C, 5 mM ATP/MgCl₂, excess unlabeled Hsl1 D-box at 48 µM, and either Ub or methyl-Ub at 125 μ M. The two mixtures were combined and then quenched after 3 min. Bands containing either total modified substrate or substrate modified with >4 Ubs were quantified and normalized relative to the wild-type levels of ubiquitination. Values were plotted using GraphPad Prism. Substrate ubiquitination reactions testing Ub-Securin degron mutants were carried out by combining 70 nM APC/C, 0.5 μM CDH1, 5 mM ATP/MgCl₂, 1 μM E1, 1 μM UBE2C, 0.5 μM Ub-Securin*, $\pm 30\,\mu\text{M}\,\text{UbV}^{\text{CDH1}}, \pm 30\,\mu\text{M}\,\text{UbV}^{\text{RING}}, \text{and}\,125\,\mu\text{M}\,\text{Ub}\,\text{added}$ to start the reaction, then quenched after 15 min. Ubiquitination assays testing different E2 and substrate combinations were carried out in a similar manner with 70 nM APC/C, 0.5 µM CDC20, 5 mM ATP/MgCl₂, $1 \,\mu\text{M}$ E1, $1 \,\mu\text{M}$ E2 (UBE2C, UBCH5B and/or UBE2S), 0.5 μM substrate (CycB^{N*} or Ub-CycB^{N*}, Securin* or Ub-Securin*) and $\pm 30 \ \mu M \ UbV^{CDH1}$. *UbV^{CDH1} ubiquitination reactions were carried out using 50 nM APC/C

or APC/C^{Δ WHB}, ±0.5 μ M CDH1, 7 μ M *UbV^{CDH1}, 2 μ M UBE2C and/or UBE2S, 1 μ M E1, 5 mM ATP/MgCl₂ and 125 μ m Ub, and carried out at 0, 30 and 60 min timepoints.

Intrinsic ability of APC/C to catalyze the hydrolysis of Ub from UBE2C was tested using an oxyester-linked UBE2C-Ub (where - denotes oxyester linkage) in the presence and absence of coactivator or UbV^{CDH1}. Reaction mixtures contained 1 μ M APC/C, 5 μ M UBE2C-Ub and \pm 10 μ M UbV^{CDH1} and were quenched after 0, 3 or 5 h at room temperature and visualized using SDS-PAGE and Coomassie staining. Di-Ub synthesis assays were carried out as described previously, with the addition of \pm 10 μ M UbV^{CDH1}(ref. 23).

Phage display

The UbV library was based upon the same design as library 2 generated by Ernst et al.⁵⁰. Phage display selection was carried out according to established protocols⁴⁸. Briefly, 1 µM purified CDH1 and CDC20 were coated on 96-well MaxiSorp plates (Thermo Scientific) by incubating overnight at 4 °C. Five rounds of selection using the phage-displayed UbV library were performed against immobilized proteins. The coated wells were blocked with PBS-B (phosphate-buffered saline (PBS) supplemented with 1% BSA) and incubated at 4 °C for 1 h. The original phage display library (first round) or the enriched input from the previous round (subsequent rounds) was added to each coated well and incubated for 1 h at room temperature. Non-bound phages were removed by washing the coated wells with PBS-T (PBS supplemented with 0.05% Tween-20). Washing stringency was increased with each round. To elute the bound phage, 0.1 M HCl was added to each coated well and incubated for 5 min at room temperature. The pH was neutralized by adding 1 M Tris-HCl (pH 11), and BSA was added to eluted phage to a final concentration of 1%. Amplifying the eluted phage to generate input phage for subsequent rounds was achieved by superinfecting E. coli OmniMax with both eluted phage and helper phage. After the fifth round of selection, phage generated in rounds 4 and 5 were analyzed by phage ELISA to obtain crude binding data and their corresponding phagemids were subjected to Sanger sequencing to obtain UbV sequences and assess binder enrichment. The CDC20 selection produced the coactivator-binding UbV used in this study.

APC/C substrate degradation assay using CP HeLaS3 extracts

The degradation assay using a checkpoint (CP) cell-free extract was performed essentially as described previously^{45,71}. HeLaS3 cells were grown at 37 °C with 5% CO₂ in Dulbecco's modified Eagle medium (DMEM, Gibco) supplemented with 10% fetal bovine serum. Confluent cells were seeded in 15 cm plates at 3 million cells per plate and treated the day after with 2 mM thymidine for 24 h. Thymidine-containing medium was removed, and cells were washed with warm PBS twice and drug-free DMEM once, and released in DMEM for 4 h. Then, cells were treated with 100 ng ml⁻¹ of nocodazole in DMEM for 11 h to obtain an early mitotic (prometaphase) population and collected for extract preparation. Mitotic cells (>95%) were collected by 'shake off', pelleted at 277g, washed with PBS once then resuspended in 1 ml of ice-cold PBS and pelleted in Eppendorf tubes. Cell pellets from 4 × 15 cm dishes were lysed in 600 µl of SB buffer (20 mM HEPES pH 7.5, 1.5 mM MgCl₂, 1 mM dithiothreitol, 5 mM KCl, 2 µg ml⁻¹ pepstatin, 2 µg ml⁻¹ apoprotinin, 10 µg ml⁻¹ leupeptin, 1 mM 4-(2 aminoethyl) benzenesulfonyl fluoride and 1 mM Na₃VO₄) supplemented with 20 µl of energy mix (375 mM creatine phosphate, 50 mM ATP and 50 mM MgCl₂, pH 8.0). Cells were incubated for 30 min on ice and flipped every 5 min before being frozen in liquid nitrogen then quickly thawed at 30 °C, and the procedure was repeated one more time. DNA was sheared by passing the lysate seven times through a 20 1/2 G and twice through a 25 3/8 G. The lysate was centrifugated at 3,075g at 4 °C for 5 min first, and its supernatant was then centrifuged at 24,104g at 4 °C for 30 min. The resulting extract was aliquoted and either stored at -80 °C or used immediately. Typically, a master mix made of 50 µl of CP extracts was supplemented

with 12 μ l of energy mix, 12 μ l of either 850 μ M Ub or UbV^{CDH1} and 3 μ l of 40 μ M UBE2C. The master mix was diluted 1:1 in fresh SB buffer minus proteases inhibitors, and reactions were incubated at 30 °C. Aliquots were taken out at the indicated times, stopped with sample buffer, boiled and analyzed by SDS–PAGE and western blot.

METRIS

The METRIS experiments were performed similarly to previously described methods⁵¹. The APC/C harbored a multipurpose tag on the C-terminus of APC4 that included a HaloTag, AviTag and Twin-Strep(II)-tag. After ion exchange chromatography described above, the APC/C was biotinylated and subjected to SEC. Ub was biotinylated on an N-terminal cysteine using biotin maleimide.

Biotinvlated Ub, CvcB or Ub-CvcB was added to fully saturate and coat streptavidin high-capacity eight-well strips and left to bind for 2 h (Sigma-Aldrich). The wells were then washed with a blocking buffer and left for 30 min after which they were washed again. The biotinylated APC/C was added in 50-fold excess to the theoretical capacity of streptavidin-coated ferromagnetic beads (Spherotech). Biotin-APC/C (3 µM) and CDH1 (15 µM) were incubated with ferromagnetic beads for 2 hours and the solution of magnetic beads was diluted 5,000-fold when the solution of magnetic beads was inserted into the well and magnetized using a permanent neodymium magnet. The well was placed into the Helmholtz-coil like apparatus and the rotating magnetic field was actuated at a frequency of 1 Hz for all experiments. Data acquisition was achieved using a camera for visualization, video capture and subsequent analysis described previously⁵¹. The RP is the distance the bead travels (Δx) divided by the maximum theoretical displacement of a sphere, calculated using the following equation:

$$\mathsf{RP} = \frac{\Delta x}{\pi D \tau \omega}$$

where *D* is the particle diameter, ω is the frequency of the rotating magnetic field and *t* is the actuation time.

Reporting summary

Further information on research design is available in the Nature Portfolio Reporting Summary linked to this article.

Data availability

The cryo-EM density maps of APC/C-CDH1-UBE2C-Ub-CycB^N and APC/C-CDH1-UBE2C-UBE2S-Ub-CycB^N were deposited in the Electron Microscopy Data Bank under accession numbers EMD-41140 and EMD-41142, respectively. The corresponding atomic coordinates were deposited in the RCSB Protein Data Bank under accession numbers 8TAR (APC/C-CDH1-UBE2C-Ub-CycB^N) and 8TAU (APC/C-CDH1-UBE2C-Ub-CycB^N) and 8TAU (APC/C-CDH1-UBE2C-Ub-CycB^N). The raw EM data, trained cryoDRGN models and generated volumes from this study are available on Electron Microscopy Public Image Archive database (EMPIAR-11660 and EMPIAR-11661). Unprocessed images and numerical raw data are provided as source data. Additional data available upon request. Source data are provided with this paper.

References

- 56. Jarvis, M. A. et al. Measuring APC/C-dependent ubiquitylation in vitro. *Methods Mol. Biol.* **1342**, 287–303 (2016).
- 57. Zivanov, J. et al. New tools for automated high-resolution cryo-EM structure determination in RELION-3. *eLife* **7**, e42166 (2018).
- Zheng, S. Q. et al. MotionCor2: anisotropic correction of beam-induced motion for improved cryo-electron microscopy. *Nat. Methods* 14, 331–332 (2017).
- 59. Bepler, T., Kelley, K., Noble, A. J. & Berger, B. Topaz-Denoise: general deep denoising models for cryoEM and cryoET. *Nat. Commun.* **11**, 5208 (2020).

Article

- Rohou, A. & Grigorieff, N. CTFFIND4: fast and accurate defocus estimation from electron micrographs. J. Struct. Biol. **192**, 216–221 (2015).
- Punjani, A., Rubinstein, J. L., Fleet, D. J. & Brubaker, M. A. cryoSPARC: algorithms for rapid unsupervised cryo-EM structure determination. *Nat. Methods* 14, 290–296 (2017).
- 62. Sanchez-Garcia, R. et al. DeepEMhancer: a deep learning solution for cryo-EM volume post-processing. *Commun. Biol.* **4**, 874 (2021).
- Croll, T. I. ISOLDE: a physically realistic environment for model building into low-resolution electron-density maps. *Acta Crystallogr. D* 74, 519–530 (2018).
- 64. Pettersen, E. F. et al. UCSF ChimeraX: structure visualization for researchers, educators, and developers. *Protein Sci.* **30**, 70–82 (2021).
- 65. Mirdita, M. et al. ColabFold: making protein folding accessible to all. *Nat. Methods* **19**, 679–682 (2022).
- 66. Edelstein, A. D. et al. Advanced methods of microscope control using muManager software. *J. Biol. Methods* **1**, e10 (2014).
- 67. Qiao, R. et al. Mechanism of APC/CCDC20 activation by mitotic phosphorylation. *Proc. Natl Acad. Sci. USA* **113**, E2570–E2578 (2016).
- 68. Olivo-Marin, J. Extraction of spots in biological images using multiscale products. *Pattern Recognit.* **35**, 1989–1996 (2002).
- Dinsmore, A. D., Weeks, E. R., Prasad, V., Levitt, A. C. & Weitz, D. A. Three-dimensional confocal microscopy of colloids. *Appl. Opt.* 40, 4152–4159 (2001).
- Motulsky, H. J. & Brown, R. E. Detecting outliers when fitting data with nonlinear regression—a new method based on robust nonlinear regression and the false discovery rate. *BMC Bioinformatics* 7, 123 (2006).
- Williamson, A., Jin, L. & Rape, M. Preparation of synchronized human cell extracts to study ubiquitination and degradation. *Methods Mol. Biol.* 545, 301–312 (2009).

Acknowledgements

We thank H. Stark for providing access to his Titan Krios and E. Schliep for assistance with it at the Max-Planck Institute for Multidisciplinary Science. We also thank H. Kotisch for cryo-EM data recording on the Titan Krios at the IMP and the Electron Microscopy Facility at Vienna BioCenter Core Facilities for access to their instruments and training. Additionally, we thank the UTSW-UNC Center for Cell Signaling Analysis (RM1GM145399) for dissemination and resources. The UbV library was generously provided by S. Sidhu (University of Toronto), and UbV^{CDH1} was selected in the lab of W. Zhang at University of Guelph, supported by a Canadian Institutes for Health Research (CIHR) Project Grant (PJT-162249). Our work is supported by NIH T32GM008570 (D.L.B. and T.B.) and NSF DGE-1650116 (T.B.); NIH T32GM135095 and the American Heart Association 23PRE1025746 (K.A.W.); NIH P30CA016086 (UNC High-throughput peptide Synthesis Facility and Array Facility); NIH R35GM122596 (K.M.H.); NIH R01GM120309 and the American Cancer Society RSG-18-220-01-TBG (M.J.E.); WWTF-LS19-029 and Boehringer Ingelheim (S.J.A., I.G. and D.H.); NIH R35GM128855 and UCRF (N.G.B.). Other than providing resources, the funders had no role in study design, data collection and analysis, or preparation of the manuscript. For the purpose of Open Access, the author has applied a CC BY public copyright licence to any Author Accepted Manuscript (AAM) version arising from this submission.

Author contributions

T.B., D.L.B., K.A.W., and L.C. prepared the reagents for APC/C-dependent polyubiquitination assays and METRIS experiments. T.B., K.A.W., D.L.B., E.P., and R.C.M.-C. performed the ubiquitination assays with advice from N.G.B. K.A.W. executed the TIRF microscopy experiments with assistance from D.L.B., B.L., N.P., P.X., and K.M.H. O.R. and W.Z. engineered the UbV^{CDH1} using phage display. T.B. conducted the cell extract experiments with advice from M.J.E. and N.G.B. I.G. and S.J.A. assisted with the preparation, collection, and analysis of the APC/C^{CDH1} sample with the UbV^{CDH1}-Hsl1 D-box. J.S.H. and J.P.S. performed the METRIS experiments and analyzed the data. T.B., K.A.W., D.L.B., E.P., R.C.M.-C., B.L., N.P., K.M.H., E.D.Z., D.H. and N.G.B. assisted with experimental design and data analysis. T.B., D.H., and N.G.B. conceived the project. T.B., D.H., and N.G.B. wrote the manuscript with assistance from all authors.

Competing interests

The authors declare no competing interests.

Additional information

Extended data is available for this paper at https://doi.org/10.1038/s41594-023-01105-5.

Supplementary information The online version contains supplementary material available at https://doi.org/10.1038/s41594-023-01105-5.

Correspondence and requests for materials should be addressed to David Haselbach or Nicholas G. Brown.

Peer review information *Nature Structural & Molecular Biology* thanks Hongtao Yu and the other, anonymous, reviewer(s) for their contribution to the peer review of this work. Dimitris Typas was the primary editor on this article and managed its editorial process and peer review in collaboration with the rest of the editorial team.

Reprints and permissions information is available at www.nature.com/reprints.



Extended Data Fig. 1|See next page for caption.

Extended Data Fig. 1 | **Processing and fitting of the APC/C from the TR-EM datasets. a** – Diagram depicting domain map of Ub-CycB^{N*}. **b**, **c** – Cryo-EM data processing workflow showing representative micrographs from the APC/C-CDH1-UBE2C and APC/C-CDH1-UBE2C-UBE2S datasets (B). Particle detection was optimized using Topaz⁵⁰ and filtered using 3 rounds of 2D classification. Representative 2D projections from the final 2D classification step show the APC/C in multiple orientations (C). **d** – Local resolution map of the consensus refinements from the datasets. **e** – FSC curves showing resolution of the 3D density maps from the consensus refinement from the APC/C-CDH1-UBE2C and APC/C-CDH1-UBE2C-UBE2S datasets. Lines show the 0.143 gold-standard and 0.5 cut-off with values denoting resolution at 0.143 cut-off. **f** – Similar to Fig. 1d, fitted model of APC/C-CDH1-UBE2C. **g** – Overlay of APC/C-CDH1-UBE2C electron density map from this study with published maps from previous studies. Values shown indicate map-to-map correlation of maps from previous studies (EMD-2925 and EMD-2929) with APC/C-CDH1-UBE2C from this data after gaussian filtering^{27,38}. **h** – Overlay of electron density maps from the APC/C-CDH1-UBE2C and APC/C-CDH1-UBE2C-UBE2S consensus refinements, value shown indicates map-to-map correlation. **i** – Models showing UBE2S-CTP bound to the APC/2/APC4 groove in previously described datasets (EMD-2925; EMD-3433)^{23,27} and here in the APC/C-CDH1-UBE2C-UBE2S dataset.



Extended Data Fig. 2 | **Heterogeneity analysis and classification of particles from the TR-EM datasets using cryoDRGN and PCA. a** – Diagram depicting the cryoDRGN data processing workflow. Particle images are mapped into a continuous low-dimensional vector space, producing a latent embedding, z. A volume decoder can then reconstruct a unique 3D volume given any value of z, for example a particle's mapped location in latent space. Principle Component Analysis (PCA) can be applied to either the set of particle latent embeddings for a dataset or a set of reconstructed 3D volumes to map the heterogeneity of the particles or volumes in a continuous manner. **b**, **c** – UMAP (left) and PCA (right) depiction of the latent space with representative volumes shown at indicated locations, for APC/C-CDH1-UBE2C (B) and APC/C-CDH1-UBE2C-UBE2S (C), explained variance (EV) noted in parentheses. **d** – PC trajectory along the second component showing the transition between a 'CRL Partial' to 'CRL Up, E2 Bound' state. Values in parentheses denote explained variance (EV). Densities CDH1, APC2, APC11, and UBE2C are colored as purple, green, blue, and cyan, respectively.



Extended Data Fig. 3 | **Movement of the APC/C during catalysis, shown in cryoDRGN volume PCA trajectories.** a – Volume PCA trajectories showing conformational changes along first four components to visualize displacement of CDH1 and the APC2 CRL along continuous conformational trajectories. Density changes localized near CDH1 and at the APC/C actives site shown in black stripes. **b** – Expected variance plotted for the first four components shown in A. **c** – Histograms showing distributions of volumes along the PCs shown in A.



Extended Data Fig. 4 | **FSC curves and UMAP particle distributions over TR-EM datasets. a** – FSC curves depicting the resolution of the consensus 3D refinements shown in Fig. 2b. Lines show the 0.143 gold-standard and 0.5 cut-off with values denoting resolution at 0.143 cut-off. **b** – UMAP visualization of the particle distributions in the latent space plotted separately by timepoint.



Extended Data Fig. 5 | See next page for caption.

Extended Data Fig. 5 | Development of TIRF-based APC/C-dependent substrate ubiquitination assay following fluorescently-labeled UBE2C. a, b - UMAP representation showing the particle distribution of the sub-states in the 'CRL Down' (A) and 'CRL Up' (B) major states. c - TIRF microscopy movies capture substrate-E2 interactions prior to complete substrate depletion. Experimental mixtures for the given conditions were split evenly between microscopy flow cells for data capture (Fig. 3d) and a ubiquitination reaction with 50 nM Biotin-CycB[№]-A488 spiked in, shown above, that was ran on an SDS-PAGE gel and fluorescently scanned. The banding of the ubiquitinated substrate is distorted due to the high BSA concentration needed for microscopy. The experiments were performed independently three times. d – Duration of detected binding events in seconds across multiple experiments and with increasing concentration of UBE2S CTP. e – There is minimal background signal from slide functionalization (left) and robust signal from immobilized substrate (center left) in the Substrate channel, as well as minimal background fluorescence from the substrate in the UBE2C channel (center right). The addition of UBE2C to immobilized substrate without APC/C-CDH1 shows minimal non-specific UBE2C binding (right). **f** – Example images showing UBE2C binding events upon addition of APC/C-CDH1 and increasing levels of UBE2S CTP. **g** – Montage showing representative time series of a UBE2C binding event in the UBE2C channel at 200 ms intervals. **h** – Montage (top) depicting duration of individual binding events in experiments described in (C) indicated by red or blue asterisk. Trace of raw intensity values (bottom) showing individual UBE2C binding events; red or blue asterisks denote corresponding binding events shown in montage (top).



Cartoon: APC/C-CDH1-Ubv^{CDH1}-Hsl1 D-box

Surface: PDB:5a31 APC/C-CDH1-Ubv^{CDH1}-Hsl1 D-box





Extended Data Fig. 6 | Previous artificially-trapped APC/C structures mimicking substrate ubiquitination. **a** – Fitted cryoEM models from previous studies of the APC/C showing monoubiquitination (left), multi-ubiquitination (center), and polyubiquitination (right)^{23,38}. An Hsl1 truncation harboring its KEN- and D-box was used as a substrate where a lysine was replaced with cysteine and crosslinked to the active site of UBE2C to mimic substrate priming (left). A similar Hsl1 truncation was genetically fused to the UbV^{RING}, purified, and crosslinked to UBE2C and Ub to mimic multi-monoubiquitination (center). For chain elongation, a UbV^{RING}-Hsl1D-box chimera harboring a K11C substitution was crosslinked to the active site of UBE2S (right). **b** – Similar to Fig. 4e, immunoblotting of APC/C-dependent substrate degradation in mitotic HeLa cell extracts reveals that this process is not inhibited by the addition of excess Ub, in contrast to the UbV^{CDH1}. The experiments were performed independently three times. **c** – Similar to Fig. **4***f*, Securin ubiquitination is inhibited more strongly by the UbVCDH1-Hsl1 D-box fusion, as monitored by fluorescent scanning of APC/C-CDH1-UBE2C-dependent ubiquitination reactions. The experiments were performed independently three times. **d** –Cryo-EM map of APC/C-CDH1-UbV^{CDH1}. Hsl1 D-box rigid body fitted with a surface representation model of UBE2C bound to APC2 (green)/APC11(blue). Left, UbV^{CDH1} (orange) is in position to receive Ub from UBE2C (cyan). Right, cryo-EM map fitted with atomic models of CDH1 (purple) and UbV^{CDH1} (orange)-Hsl1 D-box (red). Yellow rectangle indicates the KEN-box binding site of CDH1, similar to where UbV^{CDH1} binds. Uncropped gels representative of n = 3 independent experiments for C available in source data.





Extended Data Fig. 7 | **Ub binding to coactivator serves multiple purposes during APC/C-dependent polyubiquitination. a** – Quantitation of CycB^{N*} modified with >4 Ubs from single encounter assays in Fig. **5c**. Error bars: SEM. The experiments were performed independently three times. **b** – Substrateindependent, APC/C-dependent hydrolysis of an oxyester-linked Ub from UBE2C C114S is not impeded by the addition of UbV^{CDH1}, monitored by Coomassiestained SDS-PAGE gel. The experiments were performed independently three times. **c** – Synthesis of di-Ub by APC/C-UBE2S is not inhibited by UbV^{CDH1} as revealed by scanning of an SDS-PAGE gel where the acceptor Ub* is fluorescently labeled. The experiments were performed independently three times. $\mathbf{d} - UbV^{CDH1}$ inhibits APC/C-CDH1-dependent ubiquitination activity of all substrate and E2 combinations tested, monitored by fluorescent scanning. The experiments were performed independently three times. $\mathbf{e} - Ubiquitination of Ub$ -Securin and Ub-Securin D^{Mut} as shown in Fig. 5c. The experiments were performed independently three times. $\mathbf{f} - Similar$ to Fig. 5f, ubiquitination of *UbV^{CDH1} requires UBE2C and does not occur with UBE2S alone, as monitored by fluorescent scanning. Uncropped gels representative of n≥3 independent experiments for **B**-**F** available in source data.

nature portfolio

Nicholas G. Brown Corresponding author(s): David Haselbach

Last updated by author(s): Aug 21, 2023

Reporting Summary

Nature Portfolio wishes to improve the reproducibility of the work that we publish. This form provides structure for consistency and transparency in reporting. For further information on Nature Portfolio policies, see our <u>Editorial Policies</u> and the <u>Editorial Policy Checklist</u>.

Statistics

For	all st	atistical analyses, confirm that the following items are present in the figure legend, table legend, main text, or Methods section.
n/a	Cor	firmed
	\boxtimes	The exact sample size (n) for each experimental group/condition, given as a discrete number and unit of measurement
	\boxtimes	A statement on whether measurements were taken from distinct samples or whether the same sample was measured repeatedly
		The statistical test(s) used AND whether they are one- or two-sided Only common tests should be described solely by name; describe more complex techniques in the Methods section.
\boxtimes		A description of all covariates tested
	\boxtimes	A description of any assumptions or corrections, such as tests of normality and adjustment for multiple comparisons
		A full description of the statistical parameters including central tendency (e.g. means) or other basic estimates (e.g. regression coefficient) AND variation (e.g. standard deviation) or associated estimates of uncertainty (e.g. confidence intervals)
		For null hypothesis testing, the test statistic (e.g. F, t, r) with confidence intervals, effect sizes, degrees of freedom and P value noted Give P values as exact values whenever suitable.
\boxtimes		For Bayesian analysis, information on the choice of priors and Markov chain Monte Carlo settings
\boxtimes		For hierarchical and complex designs, identification of the appropriate level for tests and full reporting of outcomes
\boxtimes		Estimates of effect sizes (e.g. Cohen's d, Pearson's r), indicating how they were calculated
		Our web collection on <u>statistics for biologists</u> contains articles on many of the points above.

Software and code

Policy information about availability of computer code

Data collection	ThermoFisher EPU 1.9 and 2.1 software was used to collect cryoEM microscopy images. Microscopy images were collected using a microscope controlled by MicroManager 2.0.0-gamma1 software and OBIS lasers controlled using CoherentConnection v4.0.0.28 software. All fluorescent imaging was performed on an Amersham Typhoon 5. Metris experiment measurements were made using a CMOS camera.
Data analysis	Electron microscopy images were analyzed using RELION 3.0, cryosparc v4.2.1, and cryoDRGN v0.3.1. Fluorescent microscopy images were analyzed using ImageJ/FIJI 2.3.0/1.53t, Matlab 2022a (packages: Curve Fitting Toolbox v3.8, Image Processing Toolbox v11.6, Microscopy Image Browser v1.302.0.0, and the Statistics and Machine Learning Toolbox v12.4), and Graphpad Prism 9. Ubiquitinated product bands were quantified using ImageJ 2.0.0-rc-69/1.52p and data was plotted using Graphpad Prism 9. Metris measurements were analyzed using Graphpad Prism 9.

For manuscripts utilizing custom algorithms or software that are central to the research but not yet described in published literature, software must be made available to editors and reviewers. We strongly encourage code deposition in a community repository (e.g. GitHub). See the Nature Portfolio guidelines for submitting code & software for further information.

Policy information about <u>availability of data</u>

All manuscripts must include a <u>data availability statement</u>. This statement should provide the following information, where applicable:

- Accession codes, unique identifiers, or web links for publicly available datasets
- A description of any restrictions on data availability
- For clinical datasets or third party data, please ensure that the statement adheres to our policy

The cryo-EM density maps of APC/C-CDH1-UBE2C-Ubiquitin-CycBN and APC/C-CDH1-UBE2C-UBE2S-Ubiquitin-CycBN were deposited in the Electron Microscopy Data Bank under accession numbers EMD-41140 and EMD-41142, respectively. The corresponding atomic coordinates were deposited in the RCSB Protein Data Bank under accession numbers 8TAR (APC/C-CDH1-UBE2C-Ubiquitin-CycBN) and 8TAU (APC/C-CDH1-UBE2C-UBE2S-Ubiquitin-CycBN). The raw EM data, trained cryoDRGN models, and generated volumes from this study are available on Electron Microscopy Public Image Archive database (EMPIAR-11660 and EMPIAR-11661). Unprocessed images and numerical raw data are provided as source data. Additional data available upon request.

Human research participants

Policy information about studies involving human research participants and Sex and Gender in Research.

Reporting on sex and gender	N/A
Population characteristics	N/A
Recruitment	N/A
Ethics oversight	N/A

Note that full information on the approval of the study protocol must also be provided in the manuscript.

Field-specific reporting

Please select the one below that is the best fit for your research. If you are not sure, read the appropriate sections before making your selection.

Life sciences Behavioural & social sciences Ecological, evolutionary & environmental sciences

For a reference copy of the document with all sections, see <u>nature.com/documents/nr-reporting-summary-flat.pdf</u>

Life sciences study design

All studies must disclose on these points even when the disclosure is negative.

Sample size	Sample sizes are indicated in relevant figure and methods sections.
Data exclusions	No data was excluded.
Replication	All experiments were repeated at least three times, all attempts to repeat these experiments were successful.
Randomization	Randomization was not necessary or required for the data analyzed in this study, grouped data was not included in the study.
Blinding	Blinding was not relevant to our study, grouped data was not used in the study.

Reporting for specific materials, systems and methods

We require information from authors about some types of materials, experimental systems and methods used in many studies. Here, indicate whether each material, system or method listed is relevant to your study. If you are not sure if a list item applies to your research, read the appropriate section before selecting a response.

Materials & experimental systems	Methods
n/a Involved in the study	n/a Involved in the study
Antibodies	ChIP-seq
Eukaryotic cell lines	Flow cytometry
Palaeontology and archaeology	MRI-based neuroimaging
Animals and other organisms	
Clinical data	
Dual use research of concern	

Antibodies

Antibodies used	α-Securin 1:1,000 dilution (sc-56207), α-Vinculin 1:5,000 dilution (sc-25336), α-Geminin 1:5,000 (sc-13015), α-CyclinB 1:10,000 dilution (ab32053), α-Cyclin A 1:5,000 dilution (sc-751)
Validation	Validation of the antibodies was performed by the manufacturer. Western blotting results were consistent with Coomassie stained SDS PAGE analysis and known cell cycle degradation patterns.

Eukaryotic cell lines

Policy information about cell lines and Sex and Gender in Research		
Cell line source(s)	Insect cells were from life technologies, Hi Five Cat# B85502 and Sf9 Cat#11496015. HeLaS3 cells were obtained from ATCC (CCL-2.2, Manassas, Virginia)	
Authentication	None of the cell lines were authenticated.	
Mycoplasma contamination	All cells were negative for mycoplasma.	
Commonly misidentified lines (See <u>ICLAC</u> register)	No commonly misidentified lines were used.	